Reporting owner · CIK 0000882095
Gilead Sciences, Inc.
Visual SEC Form 4 history across 2 companies, 2 transactions and 2 filings.
10%ASSEMBLY BIOSCIENCES, INC.
Open-market mix
100%buys
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #87709 | ASMB | Gilead Sciences, Inc. | 10% | grant | 471k | $1.24B | A | 05/28 | 05/26 |
| #139005 | RCUS | Gilead Sciences, Inc. | 10% | buy | 1.36M | $1.49B | P | 02/21/2025 | 02/18/2025 |
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at Arcus Biosciences, Inc. on Feb 18, 2025 valued at $14,999,996.
Review SEC filingLatest sale
No open-market insider sale is available.
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for some of their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
1 observations · May 26, 2026 – May 26, 2026. Window ends at the latest available report, not today.
Selected observation · May 26, 20264,977,089 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| May 26, 2026 | 4,977,089 | May 28, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Feb 25
$15M
May 26
$0
Transaction texture
Ownership and ticket size
Average P/S size$15M
Median P/S size$15M
Direct2
Indirect0
May 26, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Visual map of known reporting history
Gilead Sciences, Inc. Insider Activity FAQ
SEC Form 4 context
Who is Gilead Sciences, Inc.?
Gilead Sciences, Inc. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0000882095.
Which companies has Gilead Sciences, Inc. reported transactions for?
ASSEMBLY BIOSCIENCES, INC., Arcus Biosciences, Inc.
When was Gilead Sciences, Inc.'s latest insider buy?
buy at Arcus Biosciences, Inc. on Feb 18, 2025 valued at $14,999,996.
When was Gilead Sciences, Inc.'s latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.